SecBot SecBot
8-K ·Filed May 12, 2026

LMRI

Lumexa Imaging Holdings, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed5mo ago SEC0001193125-26-219415
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue growth deceleration to 3.1% and flat Adjusted EBITDA are concerning relative to the prior quarter's 7.9% growth and 18.6% EBITDA expansion. The stock may trade down on the EPS miss and slowing momentum. Monitor the Q2 2026 print for confirmation of whether this is a temporary soft patch or a trend. The reiterated full-year guidance implies acceleration in the back half — if that does not materialize, the stock could re-rate lower.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
LMRI ▲ +43.85% at T+60d
NEUTRAL call +43.85% · α vs SPY +39.41% · entry $8.05 → $11.58
Entry = T+0 close
May 12, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.00%
$8.05
settled 6mo ago
T+5d
-13.04%
call -13.04% · α -11.89%
$7.00
settled 5mo ago
T+20d
+18.26%
call +18.26% · α +18.87%
$9.52
settled 5mo ago
T+60d
+43.85%
call +43.85% · α +39.41%
$11.58
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Lumexa Imaging reported Q1 2026 revenue of $252.5M (+3.1% YoY), slightly above consensus of $251.2M, and GAAP EPS of $0.02, below the Street consensus estimate of $0.12. The company reiterated its full-year 2026 guidance for revenue of $1.045B-$1.097B, Adjusted EBITDA of $234M-$242M, and Adjusted EPS of $0.71-$0.77. While the company flipped to GAAP net income of $1.7M from a net loss of $7.7M in the prior year, revenue growth decelerated sharply from 7.9% in Q4 2025 to 3.1% in Q1 2026, and Adjusted EBITDA was essentially flat at $51.2M vs $51.0M, signaling margin pressure.

Key Financial Metrics

EPS
$0.02
est $0.12 · -83.3%
Revenue
$252.5M
est $251.2M · +0.5% · +3.1% YoY
Rating
miss
Guidance
$1.045B-$1.097B
maintained
Free Cash Flow
-$2.4M

Key Facts

  • Q1 2026 consolidated revenues of $252.5M, up 3.1% YoY from $245.0M
  • GAAP net income of $1.7M vs net loss of $7.7M in Q1 2025
  • GAAP diluted EPS of $0.02 vs ($0.11) in prior year
  • Adjusted EPS of $0.18 per share
  • Adjusted EBITDA of $51.2M, essentially flat vs $51.0M in Q1 2025
  • Same-center advanced volume growth of 5.6% for both consolidated and system-wide
  • Full-year 2026 guidance reiterated: revenue $1.045B-$1.097B, Adjusted EBITDA $234M-$242M, Adjusted EPS $0.71-$0.77
  • Announced four additional centers: two tuck-in acquisitions and two de novos
  • Interest expense declined sharply to $16.3M from $29.8M in Q1 2025, driving the swing to net income
  • Operating cash flow improved to $2.9M from ($14.0M) in Q1 2025

Financial Impact

Revenue growth decelerated to 3.1% from 7.9% in Q4 2025; Adjusted EBITDA flat YoY; GAAP EPS of $0.02 missed Street consensus of $0.12

revenueepsadjustedEbitdaoperatingIncome

Risk Factors

  • Revenue growth deceleration from 7.9% to 3.1% sequentially
  • Adjusted EBITDA essentially flat YoY despite revenue growth, indicating margin compression
  • GAAP EPS of $0.02 missed Street consensus of $0.12
  • Full-year guidance implies significant back-half acceleration to hit the midpoint; execution risk is elevated
  • Operating cash flow remains thin at $2.9M; cash balance declined to $51.2M from $58.8M

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-219415
Document: d145661d8k.htm0001193125-26-219415
Document: 0001193125-26-219415-index-headers.html0001193125-26-219415
Document: 0001193125-26-219415-index.html0001193125-26-219415
Document: 0001193125-26-219415.txt0001193125-26-219415
8-K Data (Synthetic)0001193125-26-219415
4 reports for LMRI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for LMRI — sortable, filterable
TypeNow
Aug 12, 2026
10w ago
8-K
NEUTRAL ★ 5/10
$12.20awaiting T+60—$11.67 (−4.34%)
Jun 30, 2026
17w ago
8-K
NEUTRAL ★ 4/10
$11.59 $9.88▼ −14.75%▼ −17.63%$11.67 (+0.69%)
May 12, 2026
24w ago
8-K
NEUTRAL ★ 4/10
$8.05 $11.58▲ +43.85%▲ +39.41%$11.67 (+44.97%)
May 12, 2026
24w ago
Press Release
BEARISH ★ 7/10
$8.05 $11.58▼ −43.85%▼ −39.41%$11.67 (−44.97%)
Showing 4 of 4

US Market Status

Market Closed — Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026